Literature DB >> 12418451

Stable and long-lasting immune response in horses after DNA vaccination against equine arteritis virus.

M Giese1, U Bahr, N J Jakob, R Kehm, M Handermann, H Müller, T H Vahlenkamp, C Spiess, T H Schneider, G Schusse, G Darai.   

Abstract

Equine arteritis virus (EAV) is the causative agent of the equine viral arteritis. It is a small RNA virus with a linear, non-segmented plus RNA genome. EAV is a member of the Arteriviridae family that includes porcine reproductive and respiratory syndrome virus (PRSSV), simian haemorrhagic fever virus (SHFV) and lactate dehydrogenase virus (LDV). The viral transmission is via respiratory and reproductive routes. Clinical signs in horses vary, and severe infection can lead to abortions in pregnant mares or neonatal foal death. The aim of this study was to investigate the development of the immune response in horses after immunization with a DNA vaccine harbouring and expressing EAV Open Reading Frames (ORF) 2, 5, and 7, in combination with equine interleukin 2 (eqIL2). Three boosters followed the basic immunization in two-week intervals. Each immunization was a combination of gene gun and intramuscular injection. All horses developed a high titer of neutralizing antibodies after basic immunization within 2 weeks. Remarkably, this immune response was found to be independent of the age of animals. The youngest horse was six-years old, and the oldest twenty-two years old. A remarkable difference in the immune response between the young and old were not observed. The duration of immunity was investigated during a period of one year. After 12 months, neutralizing antibodies were still detectable in all the vaccinated horses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12418451     DOI: 10.1023/a:1020109801925

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  23 in total

1.  Large envelope glycoprotein and nucleocapsid protein of equine arteritis virus (EAV) induce an immune response in Balb/c mice by DNA vaccination; strategy for developing a DNA-vaccine against EAV-infection.

Authors:  E Tobiasch; R Kehm; U Bahr; C A Tidona; N J Jakob; M Handermann; G Darai; M Giese
Journal:  Virus Genes       Date:  2001-03       Impact factor: 2.332

2.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle.

Authors:  J A Wolff; J J Ludtke; G Acsadi; P Williams; A Jani
Journal:  Hum Mol Genet       Date:  1992-09       Impact factor: 6.150

3.  Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine.

Authors:  R R Deck; C M DeWitt; J J Donnelly; M A Liu; J B Ulmer
Journal:  Vaccine       Date:  1997-01       Impact factor: 3.641

Review 4.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

5.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.

Authors:  J D Thompson; T J Gibson; F Plewniak; F Jeanmougin; D G Higgins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

6.  Ribonucleic acid isolated by cesium chloride centrifugation.

Authors:  V Glisin; R Crkvenjakov; C Byus
Journal:  Biochemistry       Date:  1974-06-04       Impact factor: 3.162

7.  Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.

Authors:  H L Davis; M L Michel; M Mancini; M Schleef; R G Whalen
Journal:  Vaccine       Date:  1994-12       Impact factor: 3.641

8.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

9.  Genetic stability of equine arteritis virus during horizontal and vertical transmission in an outbreak of equine viral arteritis.

Authors:  Udeni B R Balasuriya; Jodi F Hedges; Steven A Nadler; William H McCollum; Peter J Timoney; N James MacLachlan
Journal:  J Gen Virol       Date:  1999-08       Impact factor: 3.891

10.  Identification and mapping of the UL56 gene transcript of herpes simplex virus type 1.

Authors:  A Rösen-Wolff; G Darai
Journal:  Virus Res       Date:  1991-03       Impact factor: 3.303

View more
  6 in total

1.  Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC.

Authors:  Sandra Müller; Roland Kehm; Michaela Handermann; Nurith J Jakob; Udo Bahr; Björn Schröder; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

2.  Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

Authors:  R H Mealey; D M Stone; M T Hines; D C Alperin; M H Littke; S R Leib; S E Leach; S A Hines
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

Review 3.  Assessment of the viral safety of antivenoms fractionated from equine plasma.

Authors:  Thierry Burnouf; Elwyn Griffiths; Ana Padilla; Salwa Seddik; Marco Antonio Stephano; José-María Gutiérrez
Journal:  Biologicals       Date:  2004-09       Impact factor: 1.856

Review 4.  DNA vaccines and their applications in veterinary practice: current perspectives.

Authors:  K Dhama; Mahesh Mahendran; P K Gupta; A Rai
Journal:  Vet Res Commun       Date:  2008-04-19       Impact factor: 2.459

Review 5.  The Key Role of Nucleic Acid Vaccines for One Health.

Authors:  Anders Fomsgaard; Margaret A Liu
Journal:  Viruses       Date:  2021-02-08       Impact factor: 5.048

Review 6.  Equine arteritis virus.

Authors:  Udeni B R Balasuriya; Yun Young Go; N James MacLachlan
Journal:  Vet Microbiol       Date:  2013-07-03       Impact factor: 3.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.